Alkermes (ALKS) drew investor attention after amending its February 2026 credit agreement, reducing interest rate spreads on its senior secured term loan A and term loan B facilities maturing in 2031.

Alkermes shares trade at US$50.18 after a 1-day share price return of 1.41%, and the stock shows strong momentum with a 90-day share price return of 35.81% and a 1-year total shareholder return of 73.21%, alongside an 82.72% total shareholder return over three years.

If this kind of move has your attention, it can be useful to see what else is gaining traction across healthcare. You can start by reviewing 42 healthcare AI stocks

After that rally and with Alkermes trading below both analyst price targets and an implied intrinsic value, the set up is clear: Is the discount a genuine opportunity or a sign that the market is rightly cautious?

Most Popular Narrative: 10.4% Undervalued

On the most followed narrative, Alkermes is priced below an estimated fair value of $56, with that view built on a detailed cash flow and earnings roadmap using an 8.24% discount rate.

The company is benefitting from margin expansion efforts and cost discipline, seen in lower cost of goods sold post divestiture of lower margin manufacturing operations, which, together with growing proprietary product sales, is driving higher net margins and increasing free cash flow generation.

Curious what underpins that $56 fair value for Alkermes? The narrative leans heavily on rising profitability, faster earnings than revenue growth, and a richer future earnings multiple. The exact assumptions might surprise you.

Result: Fair Value of $56 (UNDERVALUED)

However, Alkermes still faces meaningful risks, including heavier R&D spending on the orexin program and the possibility that key trial results or approvals disappoint.

Another View on Alkermes Valuation

There is a different read on Alkermes when looking at earnings based multiples. The stock trades on a P/E of 127.3x versus an industry average of 16.9x and a fair ratio of 48.5x. That gap points to rich expectations. Is the premium justifiable in your view?

Next Steps

With Alkermes pulling mixed reactions on value and growth, it helps to look beyond headlines and weigh the full picture yourself. If you want to see what risk and reward factors other investors are focusing on right now, take a look at the 2 key rewards and 3 important warning signs

Looking for more investment ideas beyond Alkermes?

If Alkermes has sharpened your focus, do not stop here. Use the Simply Wall St screener to quickly spot other stocks that match the kind of opportunities you care about most.

• Target potential bargains with resilient fundamentals by reviewing the 52 high quality undervalued stocks that may fit your risk and return preferences.
• Prioritize stability and capital protection by looking through the 78 resilient stocks with low risk scores that score well on resilience metrics.
• Hunt for promising businesses that are still off many investors radar by scanning the screener containing 20 high quality undiscovered gems before attention and liquidity catch up.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.